A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

被引：0
|
作者：
Junning Cao
Jian Zhang
Wei Peng
Zhiyu Chen
Songhua Fan
Weiguo Su
Ke Li
Jin Li
机构：
[1] Fudan University Shanghai Cancer Center,Department of Medical Oncology, Shanghai Medical College
[2] Hutchison MediPharma Ltd,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Fruquintinib; Phase I study; VEGFR; Advanced solid tumors; Safety and pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：259 / 269
页数：10
相关论文
共 15 条
  • [1] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors
    Cao, Junning
    Zhang, Jian
    Peng, Wei
    Chen, Zhiyu
    Fan, Songhua
    Su, Weiguo
    Li, Ke
    Li, Jin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 259 - 269
  • [2] Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial
    Ting Deng
    Le Zhang
    Yehui Shi
    Guiying Bai
    Yueyin Pan
    Aizong Shen
    Xinghua Han
    Zhaoyi Yang
    Mingxia Chen
    Hui Zhou
    Yang Luo
    Shirui Zheng
    Yi Ba
    Investigational New Drugs, 2023, 41 : 808 - 815
  • [3] Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial
    Deng, Ting
    Zhang, Le
    Shi, Yehui
    Bai, Guiying
    Pan, Yueyin
    Shen, Aizong
    Han, Xinghua
    Yang, Zhaoyi
    Chen, Mingxia
    Zhou, Hui
    Luo, Yang
    Zheng, Shirui
    Ba, Yi
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 808 - 815
  • [4] Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial
    Cao, Junning
    Guo, Hongqian
    Ji, Dongmei
    Shen, Weina
    Zhang, Shun
    Hsieh, Chih-Yi
    Cai, Sui Xiong
    Tian, Ye Edward
    Xu, Cong
    Zhang, Pin
    Xu, Binghe
    ONCOLOGIST, 2023, : e1259 - e1267
  • [5] Phase I study of every 2-or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
    Chiorean, E. G.
    Hurwitz, H. I.
    Cohen, R. B.
    Schwartz, J. D.
    Dalal, R. P.
    Fox, F. E.
    Gao, L.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1230 - 1237
  • [6] Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
    Le Tourneau, C.
    Becker, H.
    Claus, R.
    Elez, E.
    Ricci, F.
    Fritsch, R.
    Silber, Y.
    Hennequin, A.
    Tabernero, J.
    Jayadeva, G.
    Luedtke, D.
    He, M.
    Isambert, N.
    ESMO OPEN, 2022, 7 (05)
  • [7] Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
    Noboru Yamamoto
    Atsushi Horiike
    Yasuhito Fujisaka
    Haruyasu Murakami
    Tatsu Shimoyama
    Yasuhide Yamada
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 489 - 496
  • [8] Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
    Yamamoto, Noboru
    Horiike, Atsushi
    Fujisaka, Yasuhito
    Murakami, Haruyasu
    Shimoyama, Tatsu
    Yamada, Yasuhide
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) : 489 - 496
  • [9] Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
    Soria, J-C
    Cortes, J.
    Massard, C.
    Armand, J-P
    De Andreis, D.
    Ropert, S.
    Lopez, E.
    Catteau, A.
    James, J.
    Marier, J-F
    Beliveau, M.
    Martell, R. E.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 (02) : 463 - 471
  • [10] Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
    Ma, Fei
    Li, Qiao
    Chen, Shanshan
    Zhu, Wenjie
    Fan, Ying
    Wang, Jiayu
    Luo, Yang
    Xing, Puyuan
    Lan, Bo
    Li, Meiying
    Yi, Zongbi
    Cai, Ruigang
    Yuan, Peng
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) : 3105 - +
12